X
Astellas gains three cancer drugs with $405m Potenza buy
https://pharmaphorum.com/news/astellas-gains-three-cancer-drugs-with-405m-potenza-buy/
Astellas
Corporate Communications chief of Astellas, Jo Taylor moves to Cello Health Communications
Jo Taylor moves to Cello Health Communications
UK’s KaNDy Therapeutics funds mid-stage trial of HRT ‘replacement’
Biotech hopes for IPO or big pharma deal to fund phase 3
Seattle Genetics and Astellas gain Breakthrough Designation for urothelial cancer treatment
The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Astellas buys Ogeda after menopause drug impresses
Japanese pharma swoops after strong phase 2a results.
Astellas wins first Real-World Evidence prize at UK awards
UK awards first to introduce a real-world evidence category.
1 2
